Next Article in Journal
Sorafenib in the Management of Metastatic Renal Cell Carcinoma
Previous Article in Journal
Natural History and Management of Small Renal Masses
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue s1
10.3747/co.v16i0.405
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

First-Line Therapy with Sunitinib in Advanced Renal Cell Carcinoma: Interpretation of the Overall Survival Data from asco 2008

by
L. Wood
QEII Hlth Sci Ctr, Div Med Oncol, Halifax, NS B3H 2Y9, Canada
Curr. Oncol. 2009, 16(s1), 24-26; https://doi.org/10.3747/co.v16i0.405
Submission received: 4 February 2009 / Revised: 13 March 2009 / Accepted: 12 April 2009 / Published: 1 May 2009

Abstract

Sunitinib is now a standard first-line therapy for metastatic clear-cell kidney cancer. This paper focuses on interpretation of the overall survival data presented at the 2008 annual meeting of the American Society of Clinical Oncology from the pivotal phase III trial comparing sunitinib with interferon in the first-line setting. The previously published progression-free survival and response rate data from that study are also summarized.
Keywords: sunitinib; renal cell carcinoma; overall survival sunitinib; renal cell carcinoma; overall survival

Share and Cite

MDPI and ACS Style

Wood, L. First-Line Therapy with Sunitinib in Advanced Renal Cell Carcinoma: Interpretation of the Overall Survival Data from asco 2008. Curr. Oncol. 2009, 16, 24-26. https://doi.org/10.3747/co.v16i0.405

AMA Style

Wood L. First-Line Therapy with Sunitinib in Advanced Renal Cell Carcinoma: Interpretation of the Overall Survival Data from asco 2008. Current Oncology. 2009; 16(s1):24-26. https://doi.org/10.3747/co.v16i0.405

Chicago/Turabian Style

Wood, L. 2009. "First-Line Therapy with Sunitinib in Advanced Renal Cell Carcinoma: Interpretation of the Overall Survival Data from asco 2008" Current Oncology 16, no. s1: 24-26. https://doi.org/10.3747/co.v16i0.405

APA Style

Wood, L. (2009). First-Line Therapy with Sunitinib in Advanced Renal Cell Carcinoma: Interpretation of the Overall Survival Data from asco 2008. Current Oncology, 16(s1), 24-26. https://doi.org/10.3747/co.v16i0.405

Article Metrics

Back to TopTop